RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

 

NEWS PROVIDED BY

RedHill Biopharma Ltd. 

Mar 22, 2021, 07:00 ET

 

TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib[1] treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

 

Acting rapidly to ensure emergency transport and supply of drug, treatment was initiated with orally-administered opaganib within the past week. Opaganib is a novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated dual anti-inflammatory and antiviral activity, targeting a human cell component involved in viral replication and therefore expected to be effective against emerging viral variants with mutations in the spike protein.

 

 

 

Read more: https://www.prnewswire.com/news-releases/redhill-biopharma-announces-compassionate-use-treatment-with-opaganib-of-first-covid-19-patients-in-switzerland-301252751.html

As per the description of the COVID-19 Coronavirus forum:

 

A forum dedicated to information and discussion related to the current pandemic in Thailand. This is not for conspiracy theories or any form of political discussion. If your topic is region/location specific, please use that specific forum.

 

//Closed//